U.S. Food and Drug Administration

Moderna Vaccine Appears to Offer Strongest Protection Against COVID

CDC Says All Vaccines Offer Strong Resistance to the Virus According to a new report from the Centers for Disease Control and Prevention, two-dose regimens of the Moderna and Pfizer-BioNTech mRNA vaccines provided a high level of protection against COVID-19 hospitalizations in a real-world evaluation at 21 U.S. hospitals during the period between March 11 and August 15. Vaccine effectiveness against COVID-19 hospitalization for Moderna and Pfizer-BioNTech doses were 93 percent and 88 percent, respectively, whereas the single-dose Janssen vaccine had a lower effectiveness rate at 71 percent. Protection for the Pfizer-BioNTech vaccine declined four months after

Coronavirus (COVID-19) Update: FDA Provides Updated Guidance to Address the Urgent Need for Blood During the Pandemic

Based on recently completed studies and epidemiologic data, the FDA has concluded that current policies regarding certain donor eligibility criteria can be modified without compromising the safety of the blood supply. Therefore, the FDA is revising recommendations in several guidances regarding blood donor eligibility. These changes are being put forth for immediate implementation and are expected to remain in place after the COVID-19 pandemic ends, with any appropriate changes based on comments we receive and our experience implementing the guidances. At this time, the alternatives to certain donor eligibility requirements being provided generally will apply only for the duration of the declared pandemic.